Valuation: Alector, Inc.

Market Cap 328M 293M 270M 245M 457M 31.11B 466M 3.22B 1.29B 16.36B 1.23B 1.2B 51.61B P/E 2026 *
-17.7x
P/E 2027 * -2.64x
Enterprise Value 65.64M 58.79M 54.08M 49M 91.59M 6.23B 93.3M 645M 259M 3.28B 246M 241M 10.34B EV / Sales 2026 *
0.99x
EV / Sales 2027 * 1.46x
Free-Float
92.62%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Alector, Inc.

1 day-1.34%
1 week+20.77%
1 month+18.82%
3 months+46.36%
6 months-6.36%
Current year+41.67%
1 week 1.82
Extreme 1.82
2.32
1 month 1.72
Extreme 1.72
2.73
Current year 1.37
Extreme 1.37
2.76
1 year 1.09
Extreme 1.09
2.76
3 years 0.87
Extreme 0.87
8.9
5 years 0.87
Extreme 0.87
27
10 years 0.87
Extreme 0.87
43.32
Manager TitleAgeSince
Chief Executive Officer 71 01/05/2013
Director of Finance/CFO 52 20/06/2025
Chief Tech/Sci/R&D Officer - 01/01/2017
Director TitleAgeSince
Director/Board Member 71 01/05/2013
Director/Board Member 72 01/10/2018
Chairman 77 13/06/2023
Date Insider Type Main position Quantity % Market Cap. Importance
14/10/26 Free

Controller/Auditor

138,990 0.1245%
14/10/26 Free

Founder

1,196,250 1.0714%
14/10/26 Free

Chief Financial Officer

234,567 0.2101%
Change 5-day change 1-year change 3-year change Capi.($)
-1.34%+20.77%+50.34%-59.52% 328M
-0.62%-1.87%+42.87%+67.17% 63.77B
+0.35%+3.20%+14.40%+73.89% 56.37B
+0.53%+1.96%+16.24%+102.20% 54.62B
-2.81%-4.31%+23.50%+48.51% 44.06B
-0.33%-1.93%+19.28%+104.26% 42.11B
+0.55%+2.31%+225.14%+840.10% 41B
+3.27%+47.96%+112.84%+91.02% 34.92B
+1.22%-1.44%+14.57%+47.05% 32.82B
+0.89%+20.55%-40.62%+350.50% 24.7B
Average +0.17%+8.86%+47.85%+166.52% 39.47B
Weighted average by Cap. +0.18%+5.46%+47.99%+173.22%

Financials

2026 *2027 *
Net sales 66.15M 59.24M 54.5M 49.38M 92.3M 6.28B 94.03M 650M 261M 3.3B 248M 243M 10.42B 14.97M 13.41M 12.33M 11.17M 20.89M 1.42B 21.28M 147M 59.03M 748M 56.18M 54.98M 2.36B
Net income -14.22M -12.73M -11.71M -10.61M -19.84M -1.35B -20.21M -140M -56.07M -710M -53.35M -52.22M -2.24B -111M -99.31M -91.35M -82.77M -155M -10.53B -158M -1.09B -437M -5.54B -416M -407M -17.47B
Net Debt -262M -235M -216M -196M -366M -24.88B -372M -2.57B -1.03B -13.09B -983M -962M -41.27B -306M -274M -252M -228M -427M -29.04B -435M -3B -1.21B -15.28B -1.15B -1.12B -48.17B
Projected Income Statement - Annual - Alector, Inc.
Logo Alector, Inc.
Alector, Inc. is a clinical-stage biotechnology company. The Company is focused on developing therapies to counteract the devastating progression of neurodegenerative diseases. It also develops alector brain carrier (ABC), a proprietary blood-brain barrier platform, which is applied to its next-generation product candidates and research pipeline. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration. Its clinical development portfolio includes latozinemab (AL001) and AL101/GSK4527226, while its preclinical and research pipeline candidates include ADP037-ABC, ADP050-ABC, ADP056, and ADP063-ABC/ADP064-ABC. Its first product candidate, latozinemab, is a human recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of FTD-GRN patients. The AL101/GSK4527226, is a human recombinant monoclonal antibody designed to elevate PGRN levels in the brain.
Employees
103
Date Price Change Volume
30/10/26 US$2.210 -1.34% 1,111,241
29/10/26 US$2.240 -0.44% 1,460,703
28/10/26 US$2.250 +7.14% 1,910,276
27/10/26 US$2.100 +14.75% 4,569,826
26/10/26 US$1.830 -.--% 2,659,495
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Alector, Inc.
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
7
Last Close Price
2.210USD
Average target price
3.900USD
Spread / Average Target
+76.47%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Alector, Inc.
  1. Stock Market
  2. Stocks
  3. ALEC Stock